Crown Point pharma company receives $2.9M NIH grant
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
A Crown Point-based pharmaceutical company has received $2.9 million to continue its research of Alzheimer’s disease.
The National Institutes of Health’s National Institute on Aging awarded the grant to Neurodon, which will use the funding to further support study of how to improve learning and memory.
Neurodon so far has received more than $5 million in National Institute on Aging funding for its Alzheimer’s research. The company’s last grant came in August 2020.
The company’s research has led to the development of molecules it says have demonstrated neuroprotective properties and the ability to improve learning and memory in several preclinical models of Alzheimer’s.
“The NIA has been very supportive of our Alzheimer’s disease research, providing not only critical funding but also comprehensive resources for small business development,” Neurodon Vice President of Operation Colleen Mauger said in a news release. “This funding, in addition to investments we have recently received for other pipeline programs, further validates our platform and positions Neurodon well to be able to submit at least two (Investigational New Drug) applications to the FDA in the next 12-24 months.”
Neurodon said it will conduct the research in partnership with the Purdue Animal Behavioral Core, a part of the Purdue Institute for Integrative Neuroscience.